MX2021006194A - Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc. - Google Patents
Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.Info
- Publication number
- MX2021006194A MX2021006194A MX2021006194A MX2021006194A MX2021006194A MX 2021006194 A MX2021006194 A MX 2021006194A MX 2021006194 A MX2021006194 A MX 2021006194A MX 2021006194 A MX2021006194 A MX 2021006194A MX 2021006194 A MX2021006194 A MX 2021006194A
- Authority
- MX
- Mexico
- Prior art keywords
- effector cells
- enhanced
- immunotherapies
- ipsc derived
- derived effector
- Prior art date
Links
- 239000012636 effector Substances 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 238000010362 genome editing Methods 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
Abstract
Se proporcionan métodos y composiciones para obtener células efectoras derivadas funcionalmente potenciadas obtenidas de la diferenciación dirigida de las iPSC modificadas genéticamente. Las células derivadas proporcionadas en la presente descripción tienen una edición del genoma estable y funcional que ofrece efectos terapéuticos potenciados o mejorados. También se proporcionan composiciones terapéuticas y el uso de estas que comprenden las células efectoras derivadas funcionalmente potenciadas solas, o con anticuerpos o inhibidores de punto de control en terapias combinadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862774278P | 2018-12-02 | 2018-12-02 | |
PCT/US2019/063024 WO2020117526A1 (en) | 2018-12-02 | 2019-11-25 | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006194A true MX2021006194A (es) | 2021-06-30 |
Family
ID=70974390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021006194A MX2021006194A (es) | 2018-12-02 | 2019-11-25 | Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220127328A1 (es) |
EP (1) | EP3891177A4 (es) |
JP (1) | JP2022510207A (es) |
KR (1) | KR20210099601A (es) |
CN (1) | CN113166232A (es) |
AU (1) | AU2019392265A1 (es) |
BR (1) | BR112021010331A2 (es) |
CA (1) | CA3121128A1 (es) |
IL (1) | IL283607A (es) |
MX (1) | MX2021006194A (es) |
SG (1) | SG11202105480WA (es) |
WO (1) | WO2020117526A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114525255A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-11的多能干细胞衍生物及其应用 |
IL302476A (en) * | 2020-11-04 | 2023-06-01 | Fate Therapeutics Inc | Induced pluripotent stem cells and immune effector cells for heterogeneous tumor control |
US20230390337A1 (en) * | 2020-11-04 | 2023-12-07 | Fate Therapeutics, Inc. | Engineered ipsc and persistent immune effector cells |
EP4251741A1 (en) | 2020-11-30 | 2023-10-04 | CRISPR Therapeutics AG | Gene-edited natural killer cells |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
KR20230142470A (ko) * | 2021-01-29 | 2023-10-11 | 알로젠 테라퓨틱스 인코포레이티드 | 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃 |
CN117615781A (zh) * | 2021-02-25 | 2024-02-27 | 克莱格医学有限公司 | Cd94工程化细胞及其组合物 |
AU2022255166A1 (en) * | 2021-04-07 | 2023-09-28 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
WO2022263682A1 (en) * | 2021-06-18 | 2022-12-22 | Onk Therapeutics Limited | Double knockout natural killer cells |
WO2023093763A1 (en) * | 2021-11-24 | 2023-06-01 | Hangzhou Qihan Biotechnology Co., Ltd. | Systems and methods for cell-based immunotherapies cross-reference |
EP4353741A1 (en) * | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9725764D0 (en) * | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
ATE555383T1 (de) * | 2006-06-22 | 2012-05-15 | Novo Nordisk As | Lösliche heterodimere rezeptoren und ihre verwendung |
AU2017210031C1 (en) * | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
-
2019
- 2019-11-25 SG SG11202105480WA patent/SG11202105480WA/en unknown
- 2019-11-25 MX MX2021006194A patent/MX2021006194A/es unknown
- 2019-11-25 WO PCT/US2019/063024 patent/WO2020117526A1/en active Application Filing
- 2019-11-25 KR KR1020217019117A patent/KR20210099601A/ko unknown
- 2019-11-25 EP EP19893181.8A patent/EP3891177A4/en active Pending
- 2019-11-25 CN CN201980079481.0A patent/CN113166232A/zh active Pending
- 2019-11-25 JP JP2021530163A patent/JP2022510207A/ja active Pending
- 2019-11-25 AU AU2019392265A patent/AU2019392265A1/en active Pending
- 2019-11-25 CA CA3121128A patent/CA3121128A1/en active Pending
- 2019-11-25 BR BR112021010331-7A patent/BR112021010331A2/pt unknown
- 2019-11-25 US US17/297,805 patent/US20220127328A1/en active Pending
-
2021
- 2021-06-01 IL IL283607A patent/IL283607A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019392265A1 (en) | 2021-06-03 |
CN113166232A (zh) | 2021-07-23 |
JP2022510207A (ja) | 2022-01-26 |
EP3891177A1 (en) | 2021-10-13 |
US20220127328A1 (en) | 2022-04-28 |
WO2020117526A1 (en) | 2020-06-11 |
BR112021010331A2 (pt) | 2021-10-05 |
IL283607A (en) | 2021-07-29 |
SG11202105480WA (en) | 2021-06-29 |
CA3121128A1 (en) | 2020-06-11 |
KR20210099601A (ko) | 2021-08-12 |
EP3891177A4 (en) | 2023-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020005477A (es) | Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc. | |
MX2020009896A (es) | Celulas efectoras inmunitarias modificadas y usos de las mismas. | |
MX2020005701A (es) | Células efectoras inmunitarias potenciadas y usos de las mismas. | |
MX2021006194A (es) | Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc. | |
MX2022000553A (es) | Modificación de células efectoras inmunitarias y uso de las mismas. | |
MX2022003414A (es) | Celulas efectoras con multiples objetivos y uso de las mismas. | |
MX2022006725A (es) | Mejora de célula inmunitaria efectora derivada de ipsc mediante el uso de compuestos pequeños. | |
MX2021012054A (es) | Reconstitución de cd3 en ipsc y células efectoras inmunitarias modificadas. | |
MX2022015863A (es) | Combinación de tipos de células efectoras derivadas de células madre pluripotentes inducidas (ipsc) para uso en inmunoterapia. | |
MX2019011679A (es) | Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular. | |
MX2022004080A (es) | Receptor de antígeno quimérico potenciado para la modificación de células efectoras inmunitarias y uso del mismo. | |
PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
MX2020004043A (es) | Composiciones y métodos para la edición génica de hemofilia a. | |
MX2023000731A (es) | Composiciones utiles para enzimas de internalizacion. | |
MX2023005029A (es) | Celula pluripotente inducida (ipsc) modificada geneticamente y celulas efectoras inmunitarias persistentes. | |
PH12018501656A1 (en) | Methods for using fxr agonists | |
MX2023004326A (es) | Células madre pluripotentes inducidas (ipsc) multiplexadas modificadas y células efectoras inmunitarias dirigidas a tumores sólidos. | |
SA517380984B1 (ar) | طريقة لإنتاج خلايا سليفة في كبد بالغ | |
MX2020004541A (es) | Edicion de genes de celulas primarias. | |
JOP20190146A1 (ar) | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد | |
MX2017002900A (es) | Terapia genica de globina para el tratamiento de hemoglobinopatias. | |
MX2019005402A (es) | Terapias de combinacion del inhibidor de arginasa. | |
PH12019550027A1 (en) | Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer | |
MX2018000897A (es) | Celulas madre hematopoyeticas que expresan pd-l1 y usos. | |
MX2023004130A (es) | Célula madre pluripotente inducida (ipsc) modificada y células efectoras inmunitarias activadas. |